No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients.
No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients.
复制标题
DOI：
10.1002/brb3.2203
复制
发表时间：
2021-07
影响因子：
3.1
通讯作者：
Gao F
中科院分区：
文献类型：
--
作者：
Wang L;Wang S;Yang H;Han J;Zhao X;Han S;Zhang Y;Lv J;Zhang J;Li M;Ji Y;Zhou S;He X;Fang H;Yang J;Zhang Y;Zhang Q;Gao P;Gao F
To investigate the correlation between acetylcholine receptor antibodies (AChR‐Ab) concentration levels and individualized clinical symptoms in patients with AChR myasthenia gravis (AChR‐MG) in China. ELISA was used to determine the concentration of AChR‐Ab in patients with MG. The Myasthenia Gravis Foundation of America (MGFA) Clinical Classification, Quantitative Myasthenia Gravis (QMG) score, and MG‐specific activities of daily living (MG‐ADL) scoring systems were used to evaluate the clinical status of patients. Spearman correlation analysis was used to determine the correlation between the AChR‐Ab concentration and clinical score. The changes in the antibody concentration and clinical score are shown in MGFA‐antibody concentration–treatment plots. Autoantibody detection tests were performed in 67 patients, and their clinical scores were recorded. Forty‐nine patients received immunosuppressive therapy, 17 patients received pyridostigmine only, and 1 patient under thymectomy without any medication. The AChR‐Ab concentration correlated with the MGFA Classification in 5 (29.4%) patients in the pyridostigmine‐only group and 15 (30.6%) patients in the immunosuppressive drug group. The changes in the MGFA Classification preceded the changes in the AChR‐Ab concentration in 4 (23.5%) patients treated with pyridostigmine and 10 (20.4%) patients on immunosuppressive drugs. In patients on oral non‐steroidal immunosuppressants, the AChR‐Ab concentration changed by more than 50%, whereas the MGFA Classification did not increase. The AChR‐Ab concentration decreased in 17/32 (53.1%) patients after thymectomy, and then increased, whereas the AChR‐Ab concentration increased in 15/32 (46.9%) patients and the MGFA Classification decreased in 27/32 (81.8%) patients after thymectomy. The AChR‐Ab concentration presented a slight correlation with the corresponding MGFA, QMG, and MG‐ADL in patients with thymoma. In the Chinese AChR‐MG population, the Changes in the AChR‐Ab concentration in individuals with AChR‐MG did not consistently correlate with the severity of clinical symptoms. We detected AChR‐Ab concentration at least four times per patient and performed corresponding clinical evaluations on 67 patients, and MGFA‐antibody concentration–treatment plots were drawn for each patient. We found that patients receiving oral glucocorticoid doses greater than 40 mg/d and nonsteroidal immunosuppressive drugs may have increased or decreased AChR‐Ab concentrations, and the clinical symptoms often improved to varying degrees. We did not find a consistent correlation between the changes in individual AChR‐Ab concentrations and the severity of clinical symptoms in patients.
登录
查看更多内容
DOI：
10.1136/jnnp-2017-316625
发表时间：
2018-05
期刊：
Journal of neurology, neurosurgery, and psychiatry
影响因子：
--
作者：
Imai T;Utsugisawa K;Murai H;Tsuda E;Nagane Y;Suzuki Y;Minami N;Uzawa A;Kawaguchi N;Masuda M;Konno S;Suzuki H;Akaishi T;Aoki M
通讯作者：
Aoki M
影响因子：
82.9
作者：
Hoch, W;McConville, J;Vincent, A
通讯作者：
Vincent, A
影响因子：
9.9
作者：
NEWSOMDAVIS, J;PINCHING, AJ;WILSON, SG
通讯作者：
WILSON, SG
影响因子：
29
作者：
Rodríguez Cruz PM;Al-Hajjar M;Huda S;Jacobson L;Woodhall M;Jayawant S;Buckley C;Hilton-Jones D;Beeson D;Vincent A;Leite MI;Palace J
通讯作者：
Palace J
影响因子：
3.4
作者：
Kondo, K;Monden, Y
通讯作者：
Monden, Y